Biocryst Pharmaceuticals (BCRX) Net Cash Flow: 2009-2024
Historic Net Cash Flow for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to -$5.2 million.
- Biocryst Pharmaceuticals' Net Cash Flow rose 73.39% to -$17.7 million in Q4 2015 from the same period last year, while for Dec 2015 it was -$25.6 million, marking a year-over-year decrease of 176.82%. This contributed to the annual value of -$5.2 million for FY2024, which is 97.33% up from last year.
- Per Biocryst Pharmaceuticals' latest filing, its Net Cash Flow stood at -$5.2 million for FY2024, which was up 97.33% from -$194.2 million recorded in FY2023.
- Biocryst Pharmaceuticals' 5-year Net Cash Flow high stood at $233.3 million for FY2021, and its period low was -$202.1 million during FY2022.
- For the 3-year period, Biocryst Pharmaceuticals' Net Cash Flow averaged around -$133.8 million, with its median value being -$194.2 million (2023).
- Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 186.60% in 2022, then skyrocketed by 97.33% in 2024.
- Biocryst Pharmaceuticals' Net Cash Flow (MRY) stood at $158.6 million in 2020, then skyrocketed by 47.09% to $233.3 million in 2021, then crashed by 186.60% to -$202.1 million in 2022, then grew by 3.91% to -$194.2 million in 2023, then skyrocketed by 97.33% to -$5.2 million in 2024.
- Its last three reported values are -$5.2 million in FY2024, -$194.2 million for FY2023, and -$202.1 million during FY2022.